Innovac Therapeutics is at the forefront of biotechnology, focusing on the development of innovative mRNA vaccines aimed at addressing unmet medical needs. The company utilizes proprietary RNA technology platforms that enhance the design and efficacy of their vaccines. Their mRNA Design Platform employs advanced computational algorithms to optimize codon usage, secondary structures, and untranslated regions, ensuring high translation efficiency and stability of the mRNA. This meticulous design process is complemented by their Delivery System Platform, which utilizes lipid nanoparticle (LNP) encapsulation to protect the mRNA from degradation and facilitate its delivery across cellular membranes, thereby eliciting robust immune responses.

In addition to their design and delivery capabilities, Innovac Therapeutics has developed a comprehensive end-to-end RNA manufacturing process. This includes the production of raw materials, plasmid generation, transcription, mRNA purification, and LNP formulation, culminating in fill/finish operations for packaging and labeling. Their proprietary computational platform also enables the design of universal T-cell epitope vaccines, which are engineered to stimulate both CD8+ and CD4+ T-cell responses, enhancing the therapeutic potential of their vaccine candidates. Through these innovative technologies, Innovac is significantly reducing the time required to bring new vaccine candidates from concept to clinical trials, positioning itself as a leader in the global vaccine landscape.

United States

Innovac Therapeutics is a biotechnology company dedicated to developing innovative vaccines for patients with unmet medical needs, using our proprietary RNA technology.

Innovac Therapeutics

Company Details